Thrombospondin-2 and LDH are putative predictive biomarkers for treatment with everolimus in second-line metastatic clear Ccll renal cell carcinoma (MARC-2 study)

  • Simple Summary: Treatment of metastatic renal cell carcinoma (mRCC) remains a challenge due to the lack of biomarkers indicating the optimal drug for each patient. This study analyzed blood samples of patients with predominant clear cell mRCC who were treated with the mTOR inhibitor everolimus after failure of one prior tumor therapy. In an exploratory approach, predictive blood biomarkers were searched. We found lower levels of the protein thrombospondin-2 (TSP-2) at the start of the therapy and higher lactate dehydrogenase (LDH) levels in serum two weeks after therapy initiation to be associated with therapy response. Of note, these blood biomarkers had a higher predictive value than baseline patient parameters or risk classifications. Polymorphisms in the mTOR gene appeared to be associated with therapy response, but were not significant. To conclude, it seems feasible to identify patients showing longtime responses to everolimus and possible to increase tumor therapy response rates based on biomarkers for individual therapy selection. Abstract: There is an unmet need for predictive biomarkers in metastatic renal cell carcinoma (mRCC) therapy. The phase IV MARC-2 trial searched for predictive blood biomarkers in patients with predominant clear cell mRCC who benefit from second-line treatment with everolimus. In an exploratory approach, potential biomarkers were assessed employing proteomics, ELISA, and polymorphism analyses. Lower levels of angiogenesis-related protein thrombospondin-2 (TSP-2) at baseline (≤665 parts per billion, ppb) identified therapy responders with longer median progression-free survival (PFS; ≤665 ppb at baseline: 6.9 months vs. 1.8, p = 0.005). Responders had higher lactate dehydrogenase (LDH) levels in serum two weeks after therapy initiation (>27.14 nmol/L), associated with a longer median PFS (3.8 months vs. 2.2, p = 0.013) and improved overall survival (OS; 31.0 months vs. 14.0 months, p < 0.001). Baseline TSP-2 levels had a stronger relation to PFS (HR 0.36, p = 0.008) than baseline patient parameters, including IMDC score. Increased serum LDH levels two weeks after therapy initiation were the best predictor for OS (HR 0.21, p < 0.001). mTOR polymorphisms appeared to be associated with therapy response but were not significant. Hence, we identified TSP-2 and LDH as promising predictive biomarkers for therapy response on everolimus after failure of one VEGF-targeted therapy in patients with clear cell mRCC.

Download full text files

Export metadata

Author:Philip Alexander ZeuschnerORCiDGND, Sebastian Hölters, Michael Stöckle, Barbara SeligerORCiDGND, Anja Müller, Hagen Sjard BachmannGND, Viktor Grünwald, Daniel C. Christoph, Arnulf StenzlORCiDGND, Marc-Oliver GrimmORCiDGND, Fabian Brüning, Peter Jürgen GoebellORCiDGND, Marinela AugustinORCiD, Frederik RoosGND, Johanna Harde, Iris Benz-Rüd, Michael StaehlerORCiDGND, Kerstin JunkerORCiD
Parent Title (English):Cancers
Place of publication:Basel
Document Type:Article
Date of Publication (online):2021/05/25
Date of first Publication:2021/05/25
Publishing Institution:Universitätsbibliothek Johann Christian Senckenberg
Release Date:2021/08/11
Tag:biomarker; everolimus; metastatic renal cell carcinoma; phase IV; second-line
Issue:11, art. 2594
Page Number:15
First Page:1
Last Page:15
Dewey Decimal Classification:6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit
Licence (German):License LogoCreative Commons - Namensnennung 4.0